Register by Friday, April 19 & Save up to $950!
Heralding a New Era of CNS-Targeted Oligonucleotides to the Clinic and Beyond
Uniting CNS Biotech & Pharma to Fuel the Next Wave of Oligonucleotide Drug Discovery, Translation & Clinical Progress
With Biogen’s milestone approval of Tofersen leading the charge with a first-in-class clinically effective ASO for ALS, the glass ceiling of efficacious and safe oligonucleotides for CNS indications has truly been shattered
The 4th Oligonucleotides for CNS Summit is the only forum wholly dedicated to unique challenges and neuroscience innovation for this modality, delving into the hottest ASO, siRNA, saRNA, and miRNA program updates and the latest industry challenges.
This July, join 150+ senior industry leaders across discovery biology, structural chemistry, preclinical, clinical, CMC, and regulatory this year from Roche, IONIS, Janssen, Merck, Novartis, Genentech, Creyon Bio, Stoke Therapeutics, Dyne Therapeutics and many more….
Access the comprehensive agenda, speaker line-up and
pre-conference focus days.
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Top Testimonials:
Other Events in the World CNS Series:
